120 related articles for article (PubMed ID: 6547139)
1. Semisynthetic derivatives of glucagon. The contribution of histidine-1 to hormone conformation and activity.
Flanders KC; Horwitz EM; Gurd RS
J Biol Chem; 1984 Jun; 259(11):7031-7. PubMed ID: 6547139
[TBL] [Abstract][Full Text] [Related]
2. Semisynthetic derivatives of glucagon: (des-His1)N epsilon-acetimidoglucagon and N alpha-Biotinyl-N epsilon-acetimidoglucagon.
Flanders KC; Mar DH; Folz RJ; England RD; Coolican SA; Harris DE; Floyd AD; Gurd RS
Biochemistry; 1982 Aug; 21(18):4244-51. PubMed ID: 7126542
[TBL] [Abstract][Full Text] [Related]
3. Semisynthetic D-His1,N epsilon-acetimidoglucagon: structure-function relationships.
Mahrenholz AM; Flanders KC; Hoosein NM; Gurd FR; Gurd RS
Arch Biochem Biophys; 1987 Sep; 257(2):379-86. PubMed ID: 2821912
[TBL] [Abstract][Full Text] [Related]
4. Properties of amidinated glucagons.
Wright DE; Rodbell M
Eur J Biochem; 1980 Oct; 111(1):11-6. PubMed ID: 7439177
[TBL] [Abstract][Full Text] [Related]
5. The role of nonspecific hydrophobic interactions in the biological activity of N epsilon-acyl derivatives of glucagon. Studies of conformation, receptor binding, and adenylate cyclase activation.
Carrey EA; Epand RM
J Biol Chem; 1982 Sep; 257(18):10624-30. PubMed ID: 6286664
[TBL] [Abstract][Full Text] [Related]
6. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.
McKee RL; Pelton JT; Trivedi D; Johnson DG; Coy DH; Sueiras-Diaz J; Hruby VJ
Biochemistry; 1986 Apr; 25(7):1650-6. PubMed ID: 3011069
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of seven synthetic glucagon analogs, modified in position 1, 2 and/or 12, on liver and heart adenylate cyclase from rat.
Robberecht P; Waelbroeck M; Camus JC; De Neef P; Coy DH; Christophe J
Peptides; 1986; 7 Suppl 1():109-12. PubMed ID: 3018688
[TBL] [Abstract][Full Text] [Related]
8. Effect of specific trinitrophenylation of the lysine epsilon amino group of glucagon on receptor binding and adenylate cyclase activation.
Liepnieks JJ; Epand RM
Arch Biochem Biophys; 1983 Aug; 225(1):102-9. PubMed ID: 6311099
[TBL] [Abstract][Full Text] [Related]
9. Glucagon carboxyl-terminal derivatives: preparation, purification, and characterization.
England RD; Jones BN; Flanders KC; Coolican SA; Rothgeb TM; Gurd RS
Biochemistry; 1982 Mar; 21(5):940-50. PubMed ID: 7074063
[TBL] [Abstract][Full Text] [Related]
10. Glucagon amino groups. Evaluation of modifications leading to antagonism and agonism.
Bregman MD; Trivedi D; Hruby VJ
J Biol Chem; 1980 Dec; 255(24):11725-31. PubMed ID: 7440567
[TBL] [Abstract][Full Text] [Related]
11. Synthetic peptide antagonists of glucagon.
Unson CG; Andreu D; Gurzenda EM; Merrifield RB
Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4083-7. PubMed ID: 3035568
[TBL] [Abstract][Full Text] [Related]
12. Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon.
Lin MC; Wright DE; Hruby VJ; Rodbell M
Biochemistry; 1975 Apr; 14(8):1559-63. PubMed ID: 164891
[TBL] [Abstract][Full Text] [Related]
13. Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs.
Hruby VJ
Mol Cell Biochem; 1982 Apr; 44(1):49-64. PubMed ID: 6283336
[TBL] [Abstract][Full Text] [Related]
14. Structural requirements for glucagon receptor binding and activation of adenylate cyclase in liver. Study of chemically modified forms of the hormone, including N alpha-trinitrophenyl glucagon, an antagonist.
Epand RM; Rosselin G; Hoa DH; Cote TE; Laburthe M
J Biol Chem; 1981 Feb; 256(3):1128-32. PubMed ID: 6256384
[TBL] [Abstract][Full Text] [Related]
15. N alpha-Malto-glucagon and N alpha-malto, S-methyl methionine27-glucagon: preparation and characterization of two partial agonists.
Coolican SA; Gurd RS
Arch Biochem Biophys; 1984 Aug; 232(2):450-7. PubMed ID: 6380408
[TBL] [Abstract][Full Text] [Related]
16. Preparation of 2-thioltryptophan-glucagon and (tryptophan-S-glucagon)2. Differences in binding to the glucagon receptor in the hepatic adenylate cyclase system.
Wright DE; Rodbell M
J Biol Chem; 1980 Nov; 255(22):10884-7. PubMed ID: 7430160
[TBL] [Abstract][Full Text] [Related]
17. Differential acid stabilities of citraconylated amino groups of glucagon. Preparation of N alpha-citraconyl glucagon and evaluation of its biological properties.
Liepnieks JJ; Epand RM
Biochim Biophys Acta; 1982 Oct; 707(2):171-7. PubMed ID: 6291617
[TBL] [Abstract][Full Text] [Related]
18. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
[TBL] [Abstract][Full Text] [Related]
19. Conformational and biological properties of di[delta-(5-nitro-2-pyrimidyl)ornithine 17,18]glucagon. Role of the arginine residues.
Epand RM; Liepnieks JJ
J Biol Chem; 1983 Jan; 258(1):203-7. PubMed ID: 6294099
[TBL] [Abstract][Full Text] [Related]
20. The effects of the trinitrophenylation of the amino groups of glucagon on its conformational properties and on its ability to activate rat liver adenylyl cyclase.
Epand RM; Wheeler GE
Biochim Biophys Acta; 1975 May; 393(1):236-46. PubMed ID: 237568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
